In August 2025, AbbVie organized a study is to assess adverse events and change in disease activity when Telisotuzumab ...

Investigators have developed a prognostic model that may identify which patients with MIBC are suitable for bladder-preserving chemoradiation.

Artificial neural networks predicted overall and progression-free survival after chemoradiation in older adults with head and ...

Stage 2 cervical cancer is classified into 2A and 2B, based on tumor spread and size, affecting treatment decisions.

Regeneron Canada Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by public drug programs in Ontario, British Columbia, Saskatchewan, Nova Scotia, Newfoundland and ...

Regeneron Canada Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by Régie de l'assurance maladie du Québec (RAMQ) in Québec for adults with advanced non-small cell ...

Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma ...

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a significant clinical ...

About Safusidenib Safusidenib is a novel, oral, potent, brain-penetrant, targeted inhibitor of mutant IDH1. In a Phase 1 clinical study, safusidenib was well-tolerated and demonstrated anti-tumor ...

A daily pill called osimertinib (Tagrisso) is delivering far longer cancer control for adults with unresectable stage 3 EGFR-mutated non-small cell lung cancer after chemoradiation and is now ...

Investing.com -- Nanobiotix (NASDAQ:NBTX) stock jumped 11.6% Thursday after the company reported promising first data from a Phase 1 study evaluating JNJ-1900 (NBTXR3) in patients with esophageal ...